1173900-35-0

Basic information

• Product Name: 9-(1-Hydroxyethyl)-7-methyl-2-(morpholin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
• Synonyms: 9-(1-Hydroxyethyl)-7-methyl-2-(morpholin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one;9-(1-hydroxyethyl)-7-Methyl-2-Morpholino-4H-pyrido[1,2-a]pyriMidin-4-one
• CAS NO: 1173900-35-0
• Molecular Formula: C₁₅H₁₉N₃O₃
• Molecular Weight: 289.32966
• Mol File: 1173900-35-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.35
• CAS DataBase Reference: 9-(1-Hydroxyethyl)-7-methyl-2-(morpholin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 9-(1-Hydroxyethyl)-7-methyl-2-(morpholin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(1173900-35-0)
• EPA Substance Registry System: 9-(1-Hydroxyethyl)-7-methyl-2-(morpholin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one(1173900-35-0)

Safety Data

• Hazardous Substances Data: 1173900-35-0(Hazardous Substances Data)

Upstream product

• 17282-00-7 3-bromo-5-methylpyridin-2-amine 
• 663619-90-7 9-bromo-2-hydroxy-7-methyl-4H-pyrido[1,2-a]pyrimidin-4-one 
• 351002-16-9 TGX₀₆₆ 

Downstream Products

• 663620-70-0 (+/-)-2-({1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl}amino)benzoic acid 
• 663619-89-4 7-methyl-2-(4-morpholinyl)-9-[1-(phenylamino)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one 
• 1308384-65-7 TGX-D₁ 
• 1374310-69-6 C₂₉H₃₈N₄O₄ 
• 1374310-68-5 C₃₉H₅₈N₄O₄ 
• 1622905-78-5 C₂₂H₂₄N₄O₄ 
• 1622905-79-6 C₂₂H₂₃ClN₄O₄ 
• 663620-73-3 C₂₂H₂₄N₈O₂ 

Relevant articles and documents

Synthesis of new TGX-221 analogs

TGX-221 is a potent phosphoinositide 3-kinase (PI3K)β inhibitor that has great therapeutic potential to treat prostate cancer. Chemical modification of TGX-221 at positions 2 and 9 was made. Five new TGX-221 analogs with different heterocyclic substituent

Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026

The present invention relates to enantiomerically pure (?) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid or pharmaceutically acceptable salts thereof, it being in a solid state, its use in medical therapy,